title: Decay-accelerating factor 1 (Daf1) deficiency exacerbates xenobiotic-induced autoimmunity.
abstract: Absence of decay-accelerating factor 1 (Daf1) has been shown to enhance T-cell responses and autoimmunity via increased expression of specific cytokines, most notably interferon (IFN)-gamma. To determine if Daf1 deficiency can exacerbate IFN-gamma-dependent murine mercury-induced autoimmunity (mHgIA), C57/BL6 Daf1(+/+) and Daf1(-/-) mice were exposed to mercuric chloride (HgCl(2)) and examined for differences in cytokine expression, T-cell activation and features of humoral autoimmunity. In the absence of Daf1, mHgIA was exacerbated, with increased serum immunoglobulin G (IgG), anti-nuclear autoantibodies (ANAs) and anti-chromatin autoantibodies. This aggravated response could not be explained by increased T-cell activation but was associated with increased levels of IFN-gamma, interleukin (IL)-2, IL-4 and IL-10 but not IL-17 in Daf1-deficient mice. Anti-CD3/anti-CD28 costimulation of Daf1(-/-) CD4(+) T cells in vitro was also found to increase cytokine expression, but the profile was different from that of mHgIA, suggesting that the cytokine changes observed in Daf1 deficiency reflect a response to mercury. The role of Daf1 in influencing cytokine expression was further examined by stimulation of CD4(+) T cells in the presence of anti-CD3 and CD97, a molecular partner for Daf1. This resulted in increased IL-10, decreased IL-17 and IL-21 and decreased IFN-gamma. These findings demonstrate that the absence of Daf1 exacerbates mHgIA, with changes in the profile of expressed cytokines. Interaction between Daf1 and its molecular partner CD97 was found to modify expression of mHgIA-promoting cytokines, suggesting a possible approach for the suppression of overaggressive cytokine production in autoimmunity.
authors.affiliation: Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Toomey
authors.forename: David M
authors.initials: DM
authors.lastname: Cauvi
authors.forename: Wen-Chao
authors.initials: WC
authors.lastname: Song
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Pollard
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000097:blood*; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000235:genetics / Q000276:immunology; D015551:Autoimmunity / Q000187:drug effects / Q000276:immunology; D018958:CD55 Antigens / Q000235:genetics / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000276:immunology; D008627:Mercuric Chloride / Q000008:administration & dosage / Q000633:toxicity; D051379:Mice; D008810:Mice, Inbred C57BL; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D018958:CD55 Antigens; D016207:Cytokines; C521184:decay-accelerating factor 1, mouse; D008627:Mercuric Chloride
references.citation: J Biol Chem. 2007 Jul 27;282(30):22023-32
references.pmid: 17449467
references.citation: Immunol Rev. 2008 Dec;226:87-102
references.pmid: 19161418
references.citation: J Immunol. 2004 Nov 1;173(9):5880-7
references.pmid: 15494542
references.citation: Autoimmun Rev. 2007 Jan;6(3):155-61
references.pmid: 17289551
references.citation: J Immunol. 2008 Nov 1;181(9):6574-83
references.pmid: 18941248
references.citation: J Exp Med. 2005 May 16;201(10):1523-30
references.pmid: 15883171
references.citation: Clin Exp Immunol. 2005 Sep;141(3):422-31
references.pmid: 16045731
references.citation: J Clin Invest. 2002 Nov;110(9):1269-74
references.pmid: 12417565
references.citation: J Immunol. 2007 Nov 1;179(9):5793-802
references.pmid: 17947652
references.citation: Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3778-82
references.pmid: 19443714
references.citation: J Exp Med. 2005 Feb 21;201(4):567-77
references.pmid: 15710649
references.citation: J Immunol. 1998 Jul 1;161(1):234-40
references.pmid: 9647229
references.citation: J Immunol. 1991 May 1;146(9):3006-11
references.pmid: 2016536
references.citation: Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):628-33
references.pmid: 9892684
references.citation: Clin Exp Immunol. 2001 Oct;126(1):157-64
references.pmid: 11678913
references.citation: Environ Health Perspect. 2001 Jan;109(1):27-33
references.pmid: 11171521
references.citation: Ann N Y Acad Sci. 2003 Apr;987:236-9
references.pmid: 12727644
references.citation: Lab Invest. 2003 Jan;83(1):75-85
references.pmid: 12533688
references.citation: J Immunol. 2009 Nov 1;183(9):5654-61
references.pmid: 19812193
references.citation: Int Arch Allergy Appl Immunol. 1989;90(1):47-53
references.pmid: 2509376
references.citation: J Immunol. 2001 Sep 1;167(5):2791-7
references.pmid: 11509624
references.citation: Immunology. 1999 Oct;98(2):303-11
references.pmid: 10540231
references.citation: J Exp Med. 1996 Sep 1;184(3):1185-9
references.pmid: 9064337
references.citation: Am J Pathol. 2007 Apr;170(4):1258-66
references.pmid: 17392165
references.citation: J Immunol. 2008 May 1;180(9):5882-9
references.pmid: 18424707
references.citation: Am J Pathol. 2002 Sep;161(3):1077-86
references.pmid: 12213736
references.citation: Annu Rev Immunol. 2009;27:485-517
references.pmid: 19132915
references.citation: Annu Rev Immunol. 1989;7:35-58
references.pmid: 2469439
references.citation: Blood. 2005 Apr 1;105(7):2836-44
references.pmid: 15576472
references.citation: Arthritis Rheum. 2007 Jun;56(6):1934-44
references.pmid: 17530719
references.citation: Immunology. 1999 Mar;96(3):348-57
references.pmid: 10233715
references.citation: J Clin Invest. 2000 Jul;106(2):207-15
references.pmid: 10903336
references.citation: J Immunol. 2006 Jul 15;177(2):1070-7
references.pmid: 16818763
references.citation: Biochem Soc Trans. 2002 Nov;30(Pt 6):1014-9
references.pmid: 12440964